You are here

Resize Text
See all clinical trials

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

To investigate effects of SAR440340 (anti-interleukin-33 [IL‑33] monoclonal antibody [mAb]) compared with placebo, on the annualized rate of moderate-to-severe acute exacerbations of COPD (AECOPD) over up to 52 weeks of treatment.

Clinical Trial Information

Protocol
TIRB: 25487, WIRB: 20181145
Phase
2
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Investigator
Gerard Criner, MD
Coordinator
Sylvia Johnson, Tiketta McIntyre

Visit clinicaltrials.gov for full clinical trial description.

Contact

For more information about this trial or to inquire about eligibility, email breathe@temple.edu

Full Title

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)